Nitric Oxide Synthase 2-Dependent Metabolic Dysregulation, Immunosuppression, and Genomic Instability in Metastatic Triple-Negative Breast Cancer
RNA-seq (gene expression) · human · 24 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE322659_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1430832 and SRA study SRP680348. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 24 samples.
How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9556295 4T1 wild type w/o cytokine, biol rep 1 4T1 wild type w/o cytok…
- GSM9556296 4T1 wild type w/o cytokine, biol rep 2 4T1 wild type w/o cytok…
- GSM9556297 4T1 wild type w/o cytokine, biol rep 3 4T1 wild type w/o cytok…
- GSM9556298 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), biol rep 1 4T1 wild type with cyto…
- GSM9556299 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), biol rep 2 4T1 wild type with cyto…
- GSM9556300 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), biol rep 3 4T1 wild type with cyto…
- GSM9556301 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), plus NOS2 inhibitor 1400W, biol rep 1 4T1 wild type with cyto…
- GSM9556302 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), plus NOS2 inhibitor 1400W, biol rep 2 4T1 wild type with cyto…
- GSM9556303 4T1 wild type with cytokines IFNg, IL1b (20ug/ml), plus NOS2 inhibitor 1400W, biol rep 3 4T1 wild type with cyto…
- GSM9556304 4T1 NOS2 KO1 w/o cytokine, biol rep 1 4T1 NOS2 KO1 w/o cytoki…
- GSM9556305 4T1 NOS2 KO1 w/o cytokine, biol rep 2 4T1 NOS2 KO1 w/o cytoki…
- GSM9556306 4T1 NOS2 KO1 w/o cytokine, biol rep 3 4T1 NOS2 KO1 w/o cytoki…
- GSM9556307 4T1 NOS2 KO1 with cytokines IFNg, IL1b (20ug/ml), biol rep 1 4T1 NOS2 KO1 with cytok…
- GSM9556308 4T1 NOS2 KO1 with cytokines IFNg, IL1b (20ug/ml), biol rep 2 4T1 NOS2 KO1 with cytok…
- GSM9556309 4T1 NOS2 KO1 with cytokines IFNg, IL1b (20ug/ml), biol rep 3 4T1 NOS2 KO1 with cytok…
- GSM9556310 DLD1 wild type w/o cytokine, biol rep 1 DLD1 wild type w/o cyto…
- GSM9556311 DLD1 wild type w/o cytokine, biol rep 2 DLD1 wild type w/o cyto…
- GSM9556312 DLD1 wild type w/o cytokine, biol rep 3 DLD1 wild type w/o cyto…
- GSM9556313 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), biol rep 1 DLD1 wild type with cyt…
- GSM9556314 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), biol rep 2 DLD1 wild type with cyt…
- GSM9556315 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), biol rep 3 DLD1 wild type with cyt…
- GSM9556316 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), plus NOS2 inhibitor 1400W, biol rep 1 DLD1 wild type with cyt…
- GSM9556317 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), plus NOS2 inhibitor 1400W, biol rep 2 DLD1 wild type with cyt…
- GSM9556318 DLD1 wild type with cytokines IFNg, IL1b, TNFa (100ug/ml), plus NOS2 inhibitor 1400W, biol rep 3 DLD1 wild type with cyt…
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE290037 Loss of IL13RA2 promotes metastatic tumour growth in triple-negative breast cancer via increased AKT signalling 21 samples shares triple-negative, metastatic
- GSE266919 Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC] 117 samples shares triple-negative
- GSE310025 Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer [RNA-Seq] 28 samples shares triple-negative
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.